Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1952 1
1954 1
1965 1
1970 2
1975 1
1978 1
1979 1
1981 10
1982 11
1983 13
1984 18
1985 16
1986 7
1987 2
1988 2
1990 1
1991 1
1993 5
1994 1
1995 3
2001 1
2003 1
2004 3
2005 1
2006 1
2007 3
2008 2
2009 5
2010 4
2011 3
2012 4
2013 13
2014 10
2015 13
2016 17
2017 6
2018 6
2019 8
2020 13
2021 18
2022 23
2023 20
2024 25
2025 21

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

293 results

Results by year

Filters applied: . Clear all
Page 1
WHO Statement on Caesarean Section Rates.
Betran AP, Torloni MR, Zhang JJ, Gülmezoglu AM; WHO Working Group on Caesarean Section. Betran AP, et al. BJOG. 2016 Apr;123(5):667-70. doi: 10.1111/1471-0528.13526. Epub 2015 Jul 22. BJOG. 2016. PMID: 26681211 Free PMC article. No abstract available.
Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma.
Verkleij CPM, Broekmans MEC, van Duin M, Frerichs KA, Kuiper R, de Jonge AV, Kaiser M, Morgan G, Axel A, Boominathan R, Sendecki J, Wong A, Verona RI, Sonneveld P, Zweegman S, Adams HC, Mutis T, van de Donk NWCJ. Verkleij CPM, et al. Among authors: de jonge av. Blood Adv. 2021 Apr 27;5(8):2196-2215. doi: 10.1182/bloodadvances.2020003805. Blood Adv. 2021. PMID: 33890981 Free PMC article.
The bone marrow NK-cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapy.
Korst CLBM, Tahri S, Duetz C, Bruins WSC, de Jonge AV, de Jong ME, Fokkema C, Smits F, Groen K, Verkleij CPM, Frerichs KA, Papazian N, van Duin M, van Beek G, Hoogenboezem R, Baardemans T, Dal Collo G, Stoetman ECG, Cosovic M, Twickler I, Rentenaar R, Eken M, Homan-Weert PM, Saraci E, D'Agostino M, van der Velden VHJ, Sanders MA, Gay F, Broijl A, Moreau P, Sonneveld P, Zweegman S, Mutis T, Cupedo T, van de Donk NWCJ. Korst CLBM, et al. Among authors: de jonge av. Blood. 2025 Jun 19;145(25):3007-3014. doi: 10.1182/blood.2024026455. Blood. 2025. PMID: 40019438
A T-cell-based metric of immune age predicts outcomes in older patients with myeloma receiving daratumumab-based therapy.
Bruins WSC, Smits F, Duetz C, Groen K, Korst CLBM, de Jonge AV, Verkleij CPM, Rentenaar R, Cosovic M, Eken M, Twickler I, Homan-Weert PM, Sonneveld P, Moreau P, Claesen J, van de Donk NWCJ, Zweegman S, Mutis T. Bruins WSC, et al. Among authors: de jonge av. Blood. 2025 Nov 20;146(21):2517-2530. doi: 10.1182/blood.2025028587. Blood. 2025. PMID: 40829164
Midwifery care is evidence-based but under increasing pressure.
Maimburg RD, Declercq ER, de Jonge A. Maimburg RD, et al. Among authors: de jonge a. Sex Reprod Healthc. 2023 Jun;36:100858. doi: 10.1016/j.srhc.2023.100858. Epub 2023 May 16. Sex Reprod Healthc. 2023. PMID: 37209445 No abstract available.
A non-randomized risk-adjusted comparison of lenalidomide + R-CHOP versus R-CHOP for MYC-rearranged DLBCL patients.
de Jonge AV, van Werkhoven E, Dinmohamed AG, Nijland M, Zwinderman AH, Bossuyt PM, Veldhuis MS, Rutten EGGM, Mous R, Vermaat JSP, Sandberg Y, de Jongh E, Bilgin YM, Boersma R, Koene H, Kersten MJ, de Jong D, Chamuleau MED. de Jonge AV, et al. Blood Cancer J. 2023 May 22;13(1):85. doi: 10.1038/s41408-023-00854-2. Blood Cancer J. 2023. PMID: 37217463 Free PMC article.
Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment.
van der Horst HJ, de Jonge AV, Hiemstra IH, Gelderloos AT, Berry DRAI, Hijmering NJ, van Essen HF, de Jong D, Chamuleau MED, Zweegman S, Breij ECW, Roemer MGM, Mutis T. van der Horst HJ, et al. Among authors: de jonge av. Blood Cancer J. 2021 Feb 18;11(2):38. doi: 10.1038/s41408-021-00430-6. Blood Cancer J. 2021. PMID: 33602901 Free PMC article.
293 results